AURA3: Blurry vision

Project Patient Voice is intended to be used with a healthcare professional when discussing the potential symptoms related to a cancer and cancer treatment. Do not rely on Project Patient Voice alone to make decisions about medical care. Do not use Project Patient Voice to substitute for advice from your health care professional. Conclusions about patient experiences with symptoms may be limited because not all symptoms may have been captured by the patient-reported questionnaire.

← Back to summary table

Download symptom data (XLSX, 24KB)

In AURA3 Study, Patients Were Asked: "In the last 7 days, what was the SEVERITY of your BLURRY VISION at its WORST?"

Patients scored the severity of their Blurry Vision on a 5-point scale (None, Mild, Moderate, Severe, Very Severe)

Patient-Reported Nausea During the First 24 Weeks on Treatment for Patients Who Completed a Questionnaire:

Figure 1 shows the percentage of patients reporting the sevierity of their Blurry Vision at each time point. For example, at week 2, 19% of patients taking Tagrisso reported Blurry Vision (ranging from Mild to Moderate). The range of patients who had any Blurry Vision during treatment with Tagrisso was between 19% - 37%. Click here for more information on how to read the graphs below.

Figure 1. Patient-Reported Blurry Vision During the First 24 Weeks on Treatment

Two stacked bar charts, one for Tagrisso and the other for chemotherapy, showing proportion of patients reporting the severity of blurry vision at each time point through the first 24 weeks of treatment. For example, at week 2, 19% of patients taking Tagrisso reported blurry vision (ranging from mild to moderate).

All responses from patients' experiences just before and up to week 24 on-treatment were included in the analysis. Some patients did not report their symptoms every week, therefore the number of patients may vary between weeks. Furthermore, not all patients remained on the treatment for 24 weeks (e.g., some stop treatment for worsening disease) which is a reason for the change in the number of patients over the course of treatment.

Worst Response Option for Blurry Vision That Patients Reported During the First 24 Weeks on Treatment

Figure 2. Worst Patient-Reported Blurry Vision During the First 24 Weeks on Treatment

Two pie charts, one for Tagrisso and the other for chemotherapy, summarizing the percentage of patients by worst reported blurry vision during the first 24 weeks of the clinical trial. In the Tagrisso arm, None (39%), Mild (43%), Moderate (13%), Severe (5%), and Very severe (0%). In the chemotherapy arm, None (27%), Mild (45%), Moderate (16%), Severe (10%) and Very severe (2%).

Patients with at least one on-treatment Blurry Vision score were included in the analysis. Tagrisso (N=99), Chemotherapy (N=55).

Some Patients Did Not Report Blurry Vision Before Treatment:

For patients that did not report Blurry Vision before treatment, Figure 3 shows the percentage of patients reporting the severity of their Blurry Vision between weeks 1 and 24.

Figure 3. Patient-Reported Blurry Vision During the First 24 Weeks on Treatment: Patients Without Blurry Vision Before Treatment

Two stacked bar charts, one for Tagrisso and the other for chemotherapy, which includes only those patients who had no blurry vision before treatment. The bar charts show the proportion of patients reporting severity of blurry vision at each time point through 24 weeks. For example, at week 2, 10% of patients taking Tagrisso reported blurry vision (ranging from mild to moderate).

All responses from patients who did not report Blurry Vision before treatment were included in the analysis. Some patients did not report their symptoms every week, therefore the number of patients may vary between weeks. Furthermore, not all patients remained on the treatment for 24 weeks (e.g., some stop treatment for worsening disease) which is a reason for the change in the number of patients over the course of treatment.

Worst Response Option for Blurry Vision That Patients Reported During the First 24 Weeks on Treatment, for Patients Who Did Not Have Blurry Vision Before Treatment:

Figure 4. Worst Patient-Reported Blurry Vision During the First 24 Weeks on Treatment: Patients Without Blurry Vision Before Treatment

Two pie charts, one for Tagrisso and the other for chemotherapy, which includes only those patients who had no blurry vision before treatment. The pie charts summarize the percentage of patients by worst reported blurry vision. In the Tagrisso arm, None (52%), Mild (40%), Moderate (4%), Severe (4%), and Very severe (0%). In the chemotherapy arm, None (36%), Mild (47%), Moderate (10%), Severe (7%), and Very severe (0%).

Patients who had no Blurry Vision before treatment and at least one on-treatment Blurry Vision score were included in the analysis. Tagrisso (N=57), Chemotherapy (N=30).